Ontology highlight
ABSTRACT: Background
Luteinising hormone-releasing hormone agonists (LHRHa), used as androgen deprivation therapy (ADT) in prostate cancer (PCa) management, reduce serum oestradiol as well as testosterone, causing bone mineral density (BMD) loss. Transdermal oestradiol is a potential alternative to LHRHa.Objective
To compare BMD change in men receiving either LHRHa or oestradiol patches (OP).Design, setting, and participants
Men with locally advanced or metastatic PCa participating in the randomised UK Prostate Adenocarcinoma TransCutaneous Hormones (PATCH) trial (allocation ratio of 1:2 for LHRHa:OP, 2006-2011; 1:1, thereafter) were recruited into a BMD study (2006-2012). Dual-energy x-ray absorptiometry scans were performed at baseline, 1 yr, and 2 yr.Interventions
SUBMITTER: Langley RE
PROVIDER: S-EPMC4854173 | biostudies-literature | 2016 Jun
REPOSITORIES: biostudies-literature